Vitrolife

First quarter

• Sales of SEK 854 (752) million, an increase of 14%, and 9% in local currencies excluding discontinued business.
• In local currencies Consumables sales increased by 12%, Technologies 7% and Genetic Services excluding discontinued business by 7%.
• Growth, in local currencies and excluding discontinued business, in all market regions APAC 23%, Americas 6% and EMEA 1%.
• Gross margin increased to 56.8% (55.7).
• Operating income before depreciation and amortisation (EBITDA) was SEK 262 (228) million. Adjusted for non-recurring cost of SEK 20 million, EBITDA was SEK 282 million, giving an EBITDA margin of 33.0% (30.4).
• Operating cash flow increased to SEK 160 million (90).
• Net income was SEK 99 (82) million including non-recurring cost, resulting in earnings per share of SEK 0.74 (0.60), an increase of 23%.

Events after the end of the period

• The Chairman of the Board, Jón Sigurdsson is interim CEO from 1 April 2023. Bronwyn Brophy has been appointed as new CEO and will join the company on 1 August 2023.
• Board member Henrik Blomquist is the Chairman of the Board from 1 April 2023 until the annual general meeting on 27 April 2023.

Gothenburg, April 21, 2023
VITROLIFE AB (publ)
Jón Sigurdsson, interim CEO